课题基金 / 基金详情

Cell envelope synthesis and antibiotic resistance in Staphylococcus aureus

Cell envelope synthesis and antibiotic resistance in Staphylococcus aureus
金黄色葡萄球菌的细胞包膜合成和抗生素耐药性
批准号:
10323003
负责人:
Thomas McCabe Bartlett
金额:
$7.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-01-01 至 2022-12-31

项目摘要

项目成果

Thomas McCabe Bartlett的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 金黄色葡萄球菌是一种革兰氏阳性条件致病菌,可导致 医院和社区都是如此。尤其值得关注的是耐甲氧西林金黄色葡萄球菌(MRSA),它 对针对细胞壁合成的-内酰胺类抗生素具有耐药性。大多数MRSA菌株还携带额外的 耐药性标记使它们对多种抗生素产生抗药性,因此治疗选择有限。因此, 目前迫切需要开发对金黄色葡萄球菌有效的新的抗菌疗法。考虑到 细胞被膜是我们第一种也是最好的抗菌剂的靶标,这项研究旨在了解其机制。 负责其组装承诺,以发现未来抗菌剂可以针对的新漏洞 治疗。拟议的研究将涉及金黄色葡萄球菌细胞膜组装的两个基本领域和 形态发生。首先,我阐述了甲氧西林耐药因子PBP2a(a类青霉素- 结合蛋白(BPBP)与细胞壁的其余合成机制一起工作,促进对-内酰胺类药物的抗性。 -内酰胺类抗生素和甲氧西林一样,通常通过抑制bpbp的转肽酶活性发挥作用,bpbp是必不可少的。 用于形成细胞壁交联剂和抵抗膨胀压力。我的寄宿实验室最近的研究和 另一些研究表明,bPBP与所谓的“分离、延伸、分裂和 产孢子(SEDS)蛋白,将由SEDS蛋白聚合的新的肽聚糖交联到生长中 细胞壁。我的初步结果表明,对甲氧西林不敏感的PBP2a可能通过取代甲氧西林- 敏感的BPBP与SEDS蛋白FtsW(伙伴互换假说)形成复合体,恢复细胞壁 面对-内酰胺挑战的合成。其次,我将设计和使用高通量细胞学筛查 鉴定金黄色葡萄球菌新的细胞膜生物发生因子。尽管非常重要和密集 对金黄色葡萄球菌细胞膜的研究,到目前为止还没有任何这样的筛查的主题。在这里,我利用荧光- 激活细胞分选(FACS)以筛选包膜生物发生缺陷的转座子文库,然后是深度 分离突变体的转座子-基因组连接的测序(TN-seq)。这种方法已经确定了许多 具有提高的细胞裂解率和细胞分离缺陷的新突变体。初步表征 提示这些新发现的因子在染色体分离、分裂部位的放置和 细胞壁合成。对其中许多因素的详细描述很可能会在这一时期之后继续下去 在我自己的研究实验室中形成基础项目,以及提供潜在的目标 用于未来的小分子抗菌疗法。此F32应用程序的具体目标是: 目的1:确定PBP2a如何整合到天然细胞壁合成机器中。 目的2:利用细胞学筛选鉴定在细胞包膜生物发生中起作用的新因子。
英文摘要
PROJECT SUMMARY Staphylococcus aureus is a Gram-positive opportunistic pathogen responsible for life-threatening infections in hospitals and communities alike. Especially concerning are methicillin-resistant S. aureus (MRSA) strains, which are resistant to -lactam antibiotics that target cell wall synthesis. Most MRSA strains also carry additional resistance markers rendering them resistant to multiple antibiotics, so treatment options are limited. Therefore, there is an urgent need to develop new antimicrobial therapies that are effective against S. aureus. Given that the cell envelope is the target of our first and best antimicrobials, studies aimed at understanding the mechanisms responsible for its assembly promise to uncover new vulnerabilities that can be targeted by future antimicrobial therapies. The proposed research will address two fundamental areas of S. aureus cell envelope assembly and morphogenesis. First, I address the mechanism by which methicillin-resistance factor PBP2a (a class b penicillin- binding protein, or bPBP) works with the rest of the cell wall synthesis machinery to promote -lactam resistance. -lactams like methicillin normally function by inhibiting the transpeptidase activity of bPBPs, which are essential for forming cell wall crosslinks and resisting turgor pressure. Recent research from my host laboratories and others has demonstrated that bPBPs act in complex with so-called ‘separation, elongation, division, and sporulation’ (SEDS) proteins, crosslinking new peptidoglycan polymerized by SEDS proteins into the growing cell wall. My preliminary results indicate that methicillin-insensitive PBP2a may function by replacing a methicillin- sensitive bPBP in a complex with the SEDS protein FtsW (the “partner-swapping” hypothesis), restoring cell wall synthesis in the face of -lactam challenge. Second, I will design and employ high-throughput cytological screens to identify novel cell envelope biogenesis factors in S. aureus. In spite of the great importance and intensive study of S. aureus cell envelope, so far it has not been the subject of any such screen. Here, I utilize fluorescence- activated cell sorting (FACS) to screen a transposon library for envelope biogenesis defects, followed by deep sequencing of the transposon-genomic junctions of isolated mutants (Tn-seq). This approach has identified many novel mutants with an enhanced rate of cell lysis and with cell separation defects. Preliminary characterization suggests that these newly identified factors play roles in chromosome segregation, division site placement, and cell wall synthesis. The detailed characterization of many of these factors will likely continue beyond the period of this fellowship to form foundational projects in my own research laboratory, as well as provide potential targets for future small molecule antimicrobial therapies. The specific aims of this F32 application are to: AIM 1: Determine how PBP2a integrates into the native cell wall synthetic machinery. AIM 2: Identify novel factors that function in cell envelope biogenesis using cytological screens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cell envelope synthesis and antibiotic resistance in Staphylococcus aureus
  • 批准号:
    9907566
  • 项目类别:
  • 资助金额:
    $6.53万
  • 财政年份:
    2020
  • 负责人:
    Thomas McCabe Bartlett
  • 依托单位:
海外基金